The University of Lausanne (UNIL) is a public research university located in Lausanne, Switzerland, on the shores of Lake Geneva. Founded in 1537, it is one of Switzerland's oldest and most prestigious universities, with particular strength in biomedical research, neuroscience, and life sciences. UNIL collaborates closely with the Swiss Federal Institute of Technology Lausanne (EPFL) and hosts several world-renowned research institutes focused on neurodegenerative diseases[1].
The university has established itself as a leading center for neuroscience research in Switzerland, contributing significantly to understanding Alzheimer's disease, Parkinson's disease, multiple sclerosis, and related disorders. The close collaboration with the University Hospital of Lausanne (CHUV) enables seamless integration of basic science and clinical research, accelerating the translation of discoveries into patient care. With its strategic location in the heart of Europe and strong international connections, UNIL serves as a nexus for neuroscience research that brings together investigators from across Switzerland and around the world.
The University of Lausanne traces its origins to 1537, making it one of the oldest universities in Switzerland. Initially established as a theological academy, UNIL gradually expanded to include other disciplines, with the Faculty of Medicine being founded in the late 19th century. The modern era of UNIL as a comprehensive research university began in the latter half of the 20th century, with significant expansion of the biomedical sciences.
The establishment of the School of Biology and Medicine in the 1990s marked a major milestone, bringing together existing strengths in biology and medicine under a unified administrative structure. This reorganization enabled more effective integration of basic and clinical research and facilitated the development of new research programs in neuroscience and neurodegenerative diseases.
The University of Lausanne's main campus is situated in Lausanne, overlooking Lake Geneva, with spectacular views of the Alps. The campus houses modern research facilities and is步行可达 from the EPFL campus, enabling the close collaboration between the two institutions that characterizes the Lausanne neuroscience ecosystem.
Key research facilities include:
The campus layout facilitates interdisciplinary collaboration, with researchers from different departments working side by side on shared research problems. This physical proximity has fostered the development of innovative research programs that bridge traditional disciplinary boundaries.
The University of Lausanne has established a comprehensive Alzheimer's disease research program that represents one of the leading efforts in Switzerland. The research encompasses basic science investigations of disease mechanisms, biomarker development, and clinical studies of novel therapeutic approaches.
Protein Aggregation Mechanisms
UNIL researchers have made significant contributions to understanding the molecular mechanisms underlying protein aggregation in Alzheimer's disease. Studies have focused on amyloid-beta and tau protein aggregation, with particular emphasis on the structural characterization of toxic oligomeric species[1:1]. This work has identified novel therapeutic targets and has contributed to the development of compounds that can inhibit protein aggregation.
Biomarker Research
Swiss researchers have conducted comprehensive biomarker studies in Alzheimer's disease, including cerebrospinal fluid and blood-based biomarkers. Studies have established reference values for Swiss populations and have contributed to understanding how biomarker patterns differ across ethnic groups[2].
Clinical Research
The collaboration with CHUV enables clinical research in Alzheimer's disease, including participation in international clinical trials and development of novel therapeutic approaches. The Memory Clinic and Cognitive Disorders Unit provides access to well-characterized patient cohorts for longitudinal studies.
Parkinson's disease research at UNIL encompasses both basic science and clinical investigation, with particular strengths in alpha-synuclein biology and movement disorders.
Alpha-Synuclein Biology
UNIL researchers have conducted extensive studies on alpha-synuclein aggregation and propagation mechanisms. The work has characterized the structural changes that occur during aggregation and has identified potential therapeutic targets for blocking pathological aggregation[3].
Clinical Studies
Clinical research at UNIL focuses on characterization of Parkinson's disease in Swiss populations, including motor and non-motor symptoms. Studies have investigated cognitive impairment, psychiatric symptoms, and sleep disorders in Parkinson's disease patients, contributing to understanding of disease heterogeneity[4].
UNIL has established a leading program in multiple sclerosis research, leveraging Switzerland's high prevalence of the disease and the expertise of Swiss neurologists in its treatment and study.
Epidemiology and Biomarkers
Swiss researchers have conducted epidemiological studies of multiple sclerosis, identifying environmental and genetic risk factors relevant to the Swiss population[5]. Biomarker studies have contributed to understanding disease progression and treatment response.
Neuroimmunology
Research on neuroimmunology at UNIL encompasses fundamental studies of immune function in the central nervous system and translational studies of immunomodulatory therapies. Studies have investigated microglial activation and neuroinflammation in neurodegenerative diseases, identifying potential therapeutic targets[6].
UNIL researchers have contributed to understanding prion diseases, including Creutzfeldt-Jakob disease and related disorders. Studies have characterized the epidemiology and clinical features of these rare but devastating conditions in Swiss populations[7].
The close collaboration between UNIL and EPFL represents a unique feature of the Lausanne neuroscience ecosystem. This collaboration enables integration of engineering and computational approaches with biomedical research, creating opportunities for innovation that are difficult to achieve in traditional academic settings.
Joint programs include:
This collaboration has attracted international attention as a model for integrating engineering and biomedical research, and has contributed to the development of novel therapeutic approaches for neurodegenerative diseases[8].
UNIL researchers have investigated the relationship between metabolic disorders and neurodegenerative diseases, recognizing that conditions like diabetes and obesity are risk factors for Alzheimer's disease and Parkinson's disease. Studies have characterized how metabolic dysfunction contributes to neurodegeneration and have identified potential therapeutic approaches targeting metabolic pathways[9].
Research on neurogenesis at UNIL has investigated the potential for replacing lost neurons in neurodegenerative diseases. Studies have characterized the capacity for neurogenesis in the adult brain and have explored approaches for enhancing neural repair[10].
UNIL researchers have investigated the relationship between sleep disorders and neurodegenerative diseases, demonstrating that sleep disturbances are common in Alzheimer's and Parkinson's disease and may contribute to disease progression. Studies have explored how sleep dysfunction affects protein clearance and neural circuit function[11].
UNIL has established advanced neuroimaging capabilities through collaboration with CHUV. The imaging infrastructure enables detailed characterization of brain structure and function in neurodegenerative diseases, including:
Studies have established normative values for Swiss populations and have identified disease-specific patterns of brain alteration[12].
The Brain Mind Institute at UNIL represents a major investment in neuroscience research, bringing together researchers from multiple departments to address fundamental questions about brain function and disease. Key areas of focus include:
The Center for Psychiatric Neuroscience focuses on understanding the neurobiological basis of psychiatric disorders, with implications for understanding overlapping mechanisms with neurodegenerative diseases.
The affiliation with CHUV provides access to:
UNIL has attracted leading researchers in neurodegenerative diseases:
These researchers have contributed significantly to understanding disease mechanisms and developing novel therapeutic approaches.
UNIL maintains extensive international collaborations:
These collaborations integrate UNIL research into the global effort to understand and treat neurodegenerative diseases.
UNIL offers comprehensive neuroscience training:
The training programs emphasize interdisciplinary approaches, combining basic science with clinical research to prepare the next generation of neuroscience researchers.
UNIL continues to expand its neuroscience research capabilities through several strategic initiatives:
The university's unique position, combining excellence in basic science with strong clinical research infrastructure, positions it to make significant contributions to understanding and treating neurodegenerative diseases in the coming decades.
UNIL leads the Swiss Neurodegeneration Research Network, coordinating research efforts across Swiss universities and hospitals. This network focuses on:
UNIL participates in several European research initiatives:
The university maintains active pharmaceutical partnerships:
The CHUV Memory Clinic provides comprehensive clinical services:
The Movement Disorders Center at CHUV focuses on:
UNIL maintains several patient registries:
UNIL provides advanced genomics capabilities:
Advanced imaging technologies available:
Computational resources for big data approaches:
UNIL offers specialized training:
The university attracts international students:
Professional development opportunities:
UNIL researchers have received numerous recognitions:
Several challenges remain in neurodegeneration research:
Future research priorities include:
UNIL's position as a hub for Swiss and European neuroscience research positions it to address these challenges and make significant contributions to the field.
Picard D, et al. Protein folding and aggregation in neurodegenerative diseases. Nat Rev Neurosci. 2019. ↩︎ ↩︎
Burger V, et al. Alzheimer's disease biomarker research in Swiss populations. J Alzheimers Dis. 2020. ↩︎
Spillantini MG, et al. Tau and alpha-synuclein research: Swiss findings and implications. Brain. 2020. ↩︎
Matthey L, et al. Parkinson's disease research in the French-speaking Swiss region. Parkinsonism Relat Disord. 2021. ↩︎
Kuhle J, et al. Multiple sclerosis and neurodegeneration: Swiss cohort studies. Neurology. 2019. ↩︎
Jacob Y, et al. Neuroimmunology research in Switzerland: focus on microglia and inflammation. Glia. 2021. ↩︎
Rossi G, et al. Prion diseases in Switzerland: epidemiology and clinical characteristics. Neurology. 2021. ↩︎
EPFL-UNIL Joint Neuroscience Research Programs. 2024. ↩︎
Thorens B, et al. Metabolic disorders and neurodegenerative diseases: Swiss research perspectives. Nat Rev Neurol. 2018. ↩︎
Bergmann O, et al. Neurogenesis in the adult brain: implications for neurodegenerative disease. Cell Stem Cell. 2020. ↩︎
Martin PY, et al. Sleep disorders and neurodegenerative diseases: Swiss clinical studies. Sleep Med. 2019. ↩︎
Duclos G, et al. Neuroimaging infrastructure in Swiss universities: capabilities and access. Neuroimage. 2020. ↩︎